Novartis Ag · SIX:NOVN

Novartis — Investor Day (September 2008)

6 slides from Novartis's investor day presentation, Sep 3, 2008

  1. Slide 1: Expanding the Lead in Biosimilars

    Expanding the Lead in Biosimilars Sandoz Day Hannes Teissl Head Biopharmaceuticals September 3, 2008 Sandoz: A leader in biosimilars ƒ Multi-billion dollar market for biopharmaceuticals • Recombinant proteins derived from living organisms ƒ Biosimilars: Sandoz the pioneer • Follow-on versions of bio

  2. Slide 2: Unique biosimilar profile versus traditional generics

    Unique biosimilar profile versus traditional generics Small molecule generics Biosimilars Character- ƒ Easy to characterize ƒ Large, complex molecules istics ƒ Mostly without a device ƒ Device as differentiator Production ƒ Mostly chemical synthesis ƒ Grown in cell lines or microbial ƒ High producti

  3. Slide 3: Varied progress in pathways for biosimilars

    Varied progress in pathways for biosimilars ƒ Solid legal footing with pathway in place since 2004 • 7 biosimilars approved to date (growth hormone, epo) EU • Based on full comparability to reference product • Rigorous scientific review by CHMP1 ƒ Abbreviated pathway for “drugs” (FD&C2 Act) ƒ No abb

  4. Slide 4: Sandoz: Biosimilar leadership in place

    Sandoz: Biosimilar leadership in place Biotech know-how ƒ World leader in traditional fermentation technologies ƒ Interferon alpha – first recombinant made in Europe in early 1980s ƒ Three state-of-the-art production plants for recombinant proteins ƒ Benefits from internal and external collaboration

  5. Slide 5: Rising sales for pathbreaking Omnitrope

    Rising sales for pathbreaking Omnitrope® Monthly gross sales1 of Omnitrope® in USD m 4.0 3.5 Pioneering role 3.0 ƒ First approved biosimilar ever 2.5 ƒ Geographic rollout 2.0 underway ƒ Niche market, but 1.5 growing patient pool 1.0 ƒ Increasing awareness and acceptance for 0.5 biosimilars 0.0 J F M

  6. Slide 6: Committed to expanding leadership in biosimilars

    Committed to expanding leadership in biosimilars ƒ Strong platform for future success ƒ Competitive advantage with two approved biosimilars ƒ Full pipeline to seize future opportunities 11 | Sandoz Day | Hannes Teissl | September 3, 2008 6

Novartis — Investor Day (September 2008) on 6ix